WHO ICTRP trial
The influence of pancreatic function on the pharmacokinetics of ivacaftor in…
NL-OMON51011 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON51011 |
|---|---|
| Public title | The influence of pancreatic function on the pharmacokinetics of ivacaftor in patients with cystic fibrosis |
| Scientific title | The influence of pancreatic function on the pharmacokinetics of ivacaftor in patients with cystic fibrosis - IPAI |
| Primary sponsor | HagaZiekenhuis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Observational invasive |
| Countries | The Netherlands |
| Conditions | Cystic Fibrosis mucoviscidosis;10083624;Cystic Fibrosis;mucoviscidosis |
| Interventions | ;Cystic Fibrosis;Ivacaftor;Pancreatic function;Pharmacokinetics |
| Registration date | May 13, 2021 |
| Target size | 20 |
| Secondary IDs | NL77001.058.21 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: